Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss

Last update: Aug 4, 2025

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) reported its second-quarter 2025 financial results, delivering a mixed performance relative to analyst expectations. The company’s revenue and earnings per share (EPS) figures diverged from estimates, prompting a modest market reaction in after-hours trading.

Key Financial Highlights

Revenue Beat: Syndax reported Q2 2025 revenue of $37.96 million, significantly exceeding the consensus estimate of $27.36 million. This represents a 38.7% upside versus expectations.
EPS Narrower Loss Than Expected: The company posted an EPS loss of ($0.83), outperforming the estimated loss of ($1.04). While still unprofitable, the smaller-than-expected loss suggests improved operational efficiency.
Product Performance:
- Revuforj® (revumenib) generated $28.6 million in net revenue, marking a 43% quarter-over-quarter increase from Q1 2025.
- Niktimvo™ (axatilimab-csfr), commercialized by partner Incyte, contributed $36.2 million in net sales, with Syndax recognizing $9.4 million in collaboration revenue.

Market Reaction

Following the earnings release, Syndax shares declined 3.66% in after-hours trading. This reaction may reflect profit-taking after a recent uptrend—the stock had gained 5.5% over the past two weeks and 10.9% over the past month. The revenue beat and narrower EPS loss did not immediately translate into a positive market response, suggesting investors may be weighing long-term sustainability against short-term outperformance.

Analyst Estimates vs. Outlook

Looking ahead, analysts project:

Q3 2025 Revenue: $34.12 million (vs. no formal guidance from Syndax).
Full-Year 2025 Revenue: $126.61 million.

The company did not provide explicit forward guidance in its press release, making it difficult to assess whether these estimates align with management’s internal expectations.

Press Release Summary

The earnings update highlighted:

Strong commercial execution for Revuforj, reinforcing its growth trajectory in acute leukemias.
Continued momentum for Niktimvo in chronic graft-versus-host disease (cGVHD), with Incyte reporting solid early adoption.
No major clinical or regulatory updates beyond financials.

For a deeper dive into Syndax’s earnings and analyst estimates, visit the earnings page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.